Iron Carboxymaltose
Sponsors
Tel-Aviv Sourasky Medical Center, Albina Nowak, MD, University Medical Centre Ljubljana, Medical University of Vienna, Hospital Universitari de Bellvitge
Conditions
Blood LossFatigueHeart FailureHeart Failure, SystolicHypophosphatemiaIron DeficienciesIron Deficiency Anaemia in ChildbirthIron Deficiency Anemia (IDA)
Phase 1
Phase 3
Intravenous Iron Carboxymaltose, Isomaltoside and Oral Iron Sulphate for Postpartum Anemia
CompletedNCT03957057
Start: 2020-09-10End: 2022-06-15Updated: 2022-06-27
IV Iron and SGLT2 Inhibitor on Ventricular Function and Myocardial Iron Content in Heart Failure With Iron Deficiency
Not yet recruitingNCT06434025
Start: 2024-05-24End: 2026-11-24Target: 99Updated: 2024-06-03
Phase 4
Treatment With IV Iron in Hospitalized Patients With Severe Heart Failure But Without Iron Deficiency
WithdrawnNCT03042130
Start: 2016-12-14End: 2018-02-06Updated: 2018-02-28
Effect of Iron on Cerebral Dopamine Receptor Density in Non-anaemic Premenopausal Women With Low Ferritin and Fatigue
NCT03305705
Start: 2017-10-23End: 2019-08-31Target: 20Updated: 2017-10-13
Treatment of Anemia With Intravenous Iron in Patients Listed for Orthotopic Liver Transplantation
NCT04475887
Start: 2020-07-23End: 2023-05-31Target: 60Updated: 2020-07-28
IV Iron-induced Hypophosphatemia After RYGB
RecruitingNCT06350955
Start: 2024-05-02End: 2026-06-30Target: 94Updated: 2024-08-20
Ferric Carboxymaltose Versus Iron Sucrose for Treating Anemia in Pregnant Women
CompletedNCT06911034
Start: 2024-02-01End: 2024-09-30Updated: 2025-04-06